Hepatic cysts classification

Jump to navigation Jump to search

Hepatic cysts Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hepatic Cysts from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hepatic cysts classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatic cysts classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatic cysts classification

CDC on Hepatic cysts classification

Hepatic cysts classification in the news

Blogs on Hepatic cysts classification

Directions to Hospitals Treating Hepatic cysts

Risk calculators and risk factors for Hepatic cysts classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Classification

Bile Duct Hamartomas

Bile duct hamartomas (BDH) – also referred to as ‘simple cysts’ and ‘von-meyenberg complexes’ – are uncommon but not rare. They are benign and do not transform into malignancies. Small cysts can be found in as many as 7.3% of people referred for abdominal MRI while giant, symptomatic cysts are present in 0.4% of the population referred for such imaging.[1] BDH are more common in women, in a ratio of 4:1 or more, and the average age of presentation is 60 years old. [2][3] Pain is, by far, the most common presentation, but patients have also complained of jaundice, edema and have presented, rarely, with a ruptured cyst.

Cystadenoma and Cystadenocarcinomas

Less common than BDH, the largest published series describing these lesions found 18 cystadenomas and 4 cystadenocarcinomas at a large institution in Cleveland over the course of 17 years. Roughly 85% are reported in women, aged 41 to 53 years old.[4][5] The key clinical difference with cystadenomas compared to BDH is the chance that they will become malignant.

Polycystic Liver Disease

Polycystic liver diseases are genetic disorders that can be either liver-specific or part of a broader disease complex known as autosomal dominant polycystic kidney disease (ADPKD). The defects in pure polycystic liver disease are those of glycoprotein metabolism and thus the lesions are fluid-filled biliary epithelial cysts full of the byproducts of errant oligosaccharide metabolism.[6][7][8] There is recent evidence to suggest that the development of cysts is further exacerbated by a secretin mediated increase in cyclic AMP that generates increased biliary fluid prodcution[9]

The Autosomal Dominant Polycystic Kidney Disease is caused by two mutations in the ADPKD-1 gene on chromosome 16 and ADPKD-2 on chromosome 4. Polycystins, the product of these genes, are proteins expressed on the epithelium of renal tubules, hepatic bile ductules and pancreatic ducts that appear to play crucial roles in the mechanosensation of cilia. [10][11] In other words, these mutations limit the ability of the cells in these tissues to detect and react to structural distortions, leading to cystic degeneration.

Hydatid Cysts

Hydatid disease – Echinococcosis – is caused by the larval form of Echinococcus granulosus, has a worldwide distribution and is endemic in many developing countries. It is isolated to the liver in 50-70% of patients and the lungs in 20-30%.[12] If symptomatic, patients typically present with pain/discomfort, an abdominal mass, fever or, very rarely, cyst rupture.

References

  1. Tapper EB, Adsay NV, Kalb B, Martin D, Kooby D, Sarmiento JM. Symptomatic Bile Duct Hamartomas: Surgical Management in an MRI Driven Practice. J Gastrointest Surg. 2010 May 18. [Epub ahead of print]
  2. Regev A et al. Large Cystic Lesions of the Liver in Adults:A 15-Year Experience in a Tertiary Center. J Am Coll Surg 2001;193:36–45
  3. Gamblin TC, Holloway SE, Heckman JT, Geller DA. Laparoscopic resection of benign hepatic cysts: a new standard. J Am Coll Surg. Nov 2008;207(5):731-736.
  4. Devaney K, Goodman ZD, Ishak KG. Hepatobiliary cystadenoma and cystadenocarcinoma. A light microscopic and immunohistochemical study of 70 patients. Am J Pathol 1994;18:1078–1091.
  5. Vogt et al. Cystadenoma and Cystadenocarcinoma of the Liver:A Single Center Experience. J AmColl Surg 2005;200:727–733
  6. Torres VE. Treatment of polycystic liver disease: one size does not fit all. Am J Kidney Dis. 2007;49:725–728
  7. Davila S, Furu L, Gharavi AG, et al: Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet 36:575-577, 2004
  8. Li A, Davila S, Furu L, et al: Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet 72:691-703, 2003
  9. Gong AY, Tietz PS, Muff MA, et al. Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes. Am J Physiol Cell Physiol 2003;284:C1205–C1214
  10. Geng L et al. Identification and Localization of Polycystin, the PKD1 Gene Product.J. Clin. Invest.1996. 98:2674–2682
  11. Nauli SM et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nature Genetics 2003;33: 129 - 137
  12. Ammann RW, Eckert J. Cestodes. Echinococcus. Gastroenterol Clin North Am 1996;25:655–689.



Template:WikiDoc Sources